Viromed Medical AG Expands Investor Base through Share Reallocation

Viromed Medical AG, a leader in cold plasma technology, has announced the reallocation of shares owned by its CEO and founder, Uwe Perbandt. This move is aimed at broadening its shareholder base, paving the way for strategic development and future growth. Viromed, primarily funded by Perbandt since its inception in 2020, has avoided capital dilution, maintaining control over its ViroCAP® systems' market launch.

The proceeds from past share sales have been reinvested into the company via shareholder loans from Perbandt, supporting ongoing operations. Future placements of up to 500,000 shares will be managed through specialized brokers, minimizing share price impact. ICF BANK AG Wertpapierhandelsbank is slated to oversee these transactions over the next six months.